Skip to main content
. 2022 Sep 27;11(19):3011. doi: 10.3390/cells11193011

Figure 2.

Figure 2

Immune effect of cisplatin in bladder cancer is related to the activation of cGASSTING pathway. (A) Basic transcription levels of STING in bladder cancer cell line on CCLE database. (B–D) T24 and TCCSUP cell lines were treated with 2 μg/mL cisplatin for 0 h (control group), 4 h, 8 h, 12 h, 20 h, 28 h at standard condition, respectively. (B) ELISA analysis of IL-6 secretion in supernatants in cisplatin treated T24 and TCCSUP cell lines and corresponding control groups for different time points. (C) IFN Bio-assay in cisplatin treated T24 and TCCSUP cell lines and corresponding control groups for different time points. (D) qRT-PCR analysis of cytokines and chemokines expression in cisplatin treated T24 and TCCSUP cell lines and corresponding control groups for different time points. Shown are genes induced at least two repeats. (E) Immunofluorescence assay showed subcellular distribution of p65 in T24 and TCCSUP cell lines treated with 2 μg/mL cisplatin or PBS for 24 h. Scale bar represent 5 μm. (F) Western blotting results of key proteins involved in cGAS-STING pathway in T24 and TCCSUP cell lines treated with 2 μg/mL cisplatin for 0 h, 4 h, 8 h, 12 h, 24 h, respectively. GAPDH was used as control protein.